VX-993

VX-993 is an investigational small molecule drug developed by Vertex Pharmaceuticals for the treatment of pain, including acute pain and neuropathic pain such as diabetic peripheral neuropathic pain. It acts as a selective inhibitor of the Nav1.8 voltage-gated sodium channel (sodium channel protein type 10 subunit alpha), which plays a key role in the transmission of pain signals in peripheral neurons. By blocking this channel, VX-993 aims to reduce abnormal neuronal excitability associated with various types of pain. The drug is administered orally and has reached Phase 2 clinical trials for acute pain and diabetic peripheral neuropathic pain[1][2][4][5][6][8].